# New clinical insight in amyotrophic lateral sclerosis and innovative clinical development from the non-profit repurposing trial of the old drug guanabenz

## TL;DR

This paper discusses a clinical study repurposing the old drug guanabenz for amyotrophic lateral sclerosis, highlighting challenges and unexpected benefits.

## Contribution

The study demonstrates how repurposing old drugs can lead to new insights and innovations in rare disease research.

## Key findings

- The hypothesis was confirmed in a sub-population, leading to new clinical investigations.
- The study provided new disease insights that are now driving laboratory research.
- It showed the potential for academic repurposing studies to attract industry interest.

## Abstract

Drug repurposing is considered a valid approach to accelerate therapeutic solutions for rare diseases. However, it is not as widely applied as it could be, due to several barriers that discourage both industry and academic institutions from pursuing this path. Herein we present the case of an academic multicentre study that considered the repurposing of the old drug guanabenz as a therapeutic strategy in amyotrophic lateral sclerosis. The difficulties encountered are discussed as an example of the barriers that academics involved in this type of study may face. Although further development of the drug for this target population was hampered for several reasons, the study was successful in many ways. Firstly, because the hypothesis tested was confirmed in a sub-population, leading to alternative innovative solutions that are now under clinical investigation. In addition, the study was informative and provided new insights into the disease, which are now giving new impetus to laboratory research. The message from this example is that even a repurposing study with an old product has the potential to generate innovation and interest from industry partners, provided it is based on a sound rationale, the study design is adequate to ensure meaningful results, and the investigators keep the full clinical development picture in mind.